Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

Intravenous and Intratracheal Thyrotropin Releasing Hormone and Its Analog Taltirelin Reverse Opioid-Induced Respiratory Depression in Isoflurane Anesthetized Rats

James D. Boghosian, Anita Luethy and Joseph F. Cotten
Journal of Pharmacology and Experimental Therapeutics July 2018, 366 (1) 105-112; DOI: https://doi.org/10.1124/jpet.118.248377
James D. Boghosian
Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts (J.D.B., A.L., J.F.C.); and Department of Anesthesia, Kantonsspital Aarau, Aarau, Switzerland (A.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Luethy
Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts (J.D.B., A.L., J.F.C.); and Department of Anesthesia, Kantonsspital Aarau, Aarau, Switzerland (A.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph F. Cotten
Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts (J.D.B., A.L., J.F.C.); and Department of Anesthesia, Kantonsspital Aarau, Aarau, Switzerland (A.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Rat breathing response to increasing bolus dose of intravenous TRH. Normalized minute ventilation in orotracheally intubated rats, spontaneously breathing 1.5% isoflurane in air before and after intravenous TRH bolus (down arrow). Data were normalized to the averaged 15 minutes of baseline breathing prior to TRH administration. Each data point is the average of four animals, using 1 minute of averaged data from each animal (n = 4 ± S.E.M.). Asterisks (*, **, and ***) indicate statistical significance (P < 0.05, P < 0.01, and P < 0.001, respectively; one-way analysis of variance with Dunnett’s post-test) relative to the data point just prior to TRH administration. Dotted red line indicates the 100% level for reference only. In (A–D) baseline minute ventilation was 23 ± 0.4 ml/min per 100 gram (n = 16 ± S.E.M.).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Intravenous TRH reverses morphine-induced respiratory depression. Normalized minute ventilation [(MV); white circles], breathing rate [(BR); black circles], and tidal volume [(TV); red circles] in orotracheally intubated rats, spontaneously breathing 1.5% isoflurane in air before and after intravenous morphine administration [(A and C); 5 mg/kg over 5 minutes; black bar] or saline [(B); control; black bar], followed by intravenous TRH [(B and C); 1 mg/kg bolus followed by 5 mg/kg/h infusion; white bar] or saline [(A); control; white bar]. Data were normalized as in Fig. 1. Each data point is the average of four to five animals, using 1 minute of averaged data from each animal (n = 4 to 5 ± S.E.M.). Asterisks (*, **, and ***) indicate statistical significance (P < 0.05, P < 0.01, and P < 0.001, respectively; one-way analysis of variance with Dunnett’s post-test) relative to the data point just prior to morphine in (A) and TRH in (B and C). In (A–C) baseline MV, BR, and TV were 30 ± 2 ml/min per 100 gram, 70 ± 1 minute−1, and 0.4 ± 0.03 ml per 100 g, respectively (n = 13 ± S.E.M.).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Effect of intravenous morphine, TRH, and taltirelin on changes in arterial blood pH, gas, and lactate levels. Data are from the same experiment/animals represented in Figs. 2 and 4 and depict the change (Δ) in arterial blood pH, carbon dioxide, oxygen, and lactate levels (A–D) from baseline at 15 and 30 minutes (15′ and 30′) after first administration of TRH, taltirelin, or saline (control). Data are shown for saline followed by TRH (gray bars; see Fig. 2B), morphine followed by saline (black bars; see Fig. 2A), morphine followed by TRH (white bars; see Fig. 2C), and morphine followed by taltirelin (blue bars; see Fig. 4B). Each column represents the average change in blood gas values from n = 3–5 animals ± S.E.M. Asterisks (*, **, and ***) indicate statistical significance (P < 0.05, P < 0.01, and P < 0.001, respectively; ns denotes not statistically significant; one-way analysis of variance with a Sidak’s post-test) relative to animals treated with morphine only (black bars). Baseline blood gas values were pH, 7.40 ± 0.01; PaO2, 70 ± 3 mm Hg; PaCO2, 45 ± 1 mm Hg; and lactate, 1 ± 0.1 mM (n = 18 ± S.E.M.).

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Intravenous taltirelin reverses morphine-induced respiratory depression. Normalized minute ventilation [(MV); white circles], breathing rate [(BR); black circles], and tidal volume [(TV); red circles] in orotracheally intubated rats, spontaneously breathing 1.5% isoflurane in air before and after intravenous saline [(A); black bar] or intravenous morphine administration [(B); 5 mg/kg, i.v., over 1 minute; black bar], followed by intravenous taltirelin (1 mg/kg, i.v. bolus; down arrow). Data were normalized as in Fig. 1. Each data point is the average of four animals, using 1 minute of averaged data from each animal (n = 4 ± S.E.M.). Asterisks (*, **, and ***) indicate statistical significance (P < 0.05, P < 0.01, and P < 0.001, respectively; one-way analysis of variance with Dunnett’s post-test) relative to the data point immediately prior to taltirelin injection. Baseline MV, BR, and TV were 28 ± 2 ml/min per 100 gram, 71 ± 5 minute−1, and 0.4 ± 0.04 ml per 100 g, respectively (n = 8 ± S.E.M.).

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    TRH reverses lethal apnea induced by high-dose, rapid intravenous morphine administration. Normalized minute ventilation [(MV); white circles], breathing rate [(BR); black circles], and tidal volume [(TV); red circles] in orotracheally intubated rats, spontaneously breathing 1.5% isoflurane in air before and after high-dose, rapid intravenous morphine administration (5 mg/kg/min, i.v., until apnea; first down arrow), followed by intravenous TRH (2 mg/kg, i.v. bolus; second down arrow) and naloxone (0.4 mg/kg, i.v. bolus; third down arrow). Rats received, on average, 21 ± 5 mg/kg of intravenous morphine in less than 5 minutes. Data were normalized as in Fig. 1. Each data point is the average of four animals, using 1 minute of averaged data from each animal (n = 4 ± S.E.M.). Since each animal incurred apnea at a slightly different time point after start of morphine infusion, time at which TRH and naloxone where administered relative to start of morphine differed slightly between animals. Baseline MV, BR, and TV were 26 ± 1 ml/min per 100 gram, 66 ± 3 minute−1, and 0.4 ± 0.04 ml per 100 g, respectively (n = 4 ± S.E.M.).

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Intratracheally administered TRH reverses morphine-induced respiratory depression. Normalized minute ventilation [(MV); white circles], breathing rate [(BR); black circles], and tidal volume [(TV); red circles] in orotracheally intubated rats, spontaneously breathing 1.5% isoflurane in air before and after intravenous morphine administration (5 mg/kg over 5 minutes; black bar), followed by intratracheal (IT) TRH (5 mg/kg, IT bolus; white bar). Data were normalized as in Fig. 1. Each data point is the average of four animals, using 1 minute of averaged data from each animal (n = 4 ± S.E.M.). Asterisks (***) indicate statistical significance (P < 0.001; one-way analysis of variance with Dunnett’s post-test) relative to the data point just prior to TRH administration. Baseline MV, BR, and TV were 26 ± 1 ml/min per 100 gram, 66 ± 3 minute−1, and 0.4 ± 0.01 ml per 100 g, respectively (n = 4 ± S.E.M.).

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Figures -

      1. Gas flow configuration and pneumotachometer signal processing required for estimating rat ventilation.

      2. Effect of intravenous bolus TRH on breathing rate (BR; black) and tidal volume (TV; red).

      3. Effect of intravenous morphine, TRH, and taltirelin on heart rate (HR; black) and mean blood pressure (BP; white).

      4. Intravenous TRH prevents morphine-induced respiratory depression.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 366 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 366, Issue 1
1 Jul 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Intravenous and Intratracheal Thyrotropin Releasing Hormone and Its Analog Taltirelin Reverse Opioid-Induced Respiratory Depression in Isoflurane Anesthetized Rats
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

TRH Reversal of Opioid-Induced Respiratory Depression

James D. Boghosian, Anita Luethy and Joseph F. Cotten
Journal of Pharmacology and Experimental Therapeutics July 1, 2018, 366 (1) 105-112; DOI: https://doi.org/10.1124/jpet.118.248377

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

TRH Reversal of Opioid-Induced Respiratory Depression

James D. Boghosian, Anita Luethy and Joseph F. Cotten
Journal of Pharmacology and Experimental Therapeutics July 1, 2018, 366 (1) 105-112; DOI: https://doi.org/10.1124/jpet.118.248377
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glucose transport modulators and mouse behavioral testing
  • Translational PK/PD Modeling of M3258
  • Kidney protective effects of BI 685509
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics